51105-90-9

Basic information

• Product Name: METHYL 1H-PYRAZOLE-4-CARBOXYLATE
• Synonyms: METHYL 1H-PYRAZOLE-4-CARBOXYLATE;PYRAZOLE-4-CARBOXYLIC ACID METHYL ESTER;Methyl4-1H-pyrazolecarboxylate;Methyl 4-pyrazolecarboxylate;Methyl pyrazole-4-carboxylate;1H-Pyrazole-4-carboxylic acid methyl ester;4-(Methoxycarbonyl)-1H-pyrazole
• CAS NO: 51105-90-9
• Molecular Formula: C₅H₆N₂O₂
• Molecular Weight: 126.11
• Mol File: 51105-90-9.mol
• Article Data: 14

Chemical Properties

• Melting Point: 145-146℃
• Boiling Point: 271℃
• Flash Point: 118℃
• Appearance: /
• Density: 1.275
• Vapor Pressure: 0.007mmHg at 25°C
• Refractive Index: 1.53
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: 11.59±0.50(Predicted)
• CAS DataBase Reference: METHYL 1H-PYRAZOLE-4-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL 1H-PYRAZOLE-4-CARBOXYLATE(51105-90-9)
• EPA Substance Registry System: METHYL 1H-PYRAZOLE-4-CARBOXYLATE(51105-90-9)

Safety Data

• Hazardous Substances Data: 51105-90-9(Hazardous Substances Data)

Usage

Description

Methyl 1H-pyrazole-4-carboxylate is an organic compound with the molecular formula C5H6N2O2. It is a derivative of 1H-pyrazole, featuring a carboxylate group attached to the 4-position and a methyl group as a substituent. Methyl 1H-pyrazole-4-carboxylate is known for its potential applications in the pharmaceutical and chemical industries due to its unique chemical structure and properties.

Uses

1. Used in Pharmaceutical Industry:
Methyl 1H-pyrazole-4-carboxylate is used as a chemical intermediate for the synthesis of aminomethylpiperidines, which are known as β3-agonists. These β3-agonists have potential applications in the treatment of various medical conditions, such as obesity and overactive bladder, by stimulating the β3-adrenergic receptors.
2. Used in Chemical Research:
Methyl 1H-pyrazole-4-carboxylate is also a potential inhibitor of liver alcohol dehydrogenase, an enzyme involved in the metabolism of alcohol. Inhibiting this enzyme could have implications for the development of treatments for alcohol use disorder and other alcohol-related health issues. As a result, this compound may be valuable in the field of chemical research, particularly in the development of new therapeutic strategies for alcohol-related conditions.

InChI:InChI=1/C5H6N2O2/c1-9-5(8)4-2-6-7-3-4/h2-3H,1H3,(H,6,7)

Upstream product

• 80981-25-5 1,3-Dimethyl-1-(1H-pyrazole-4-carbonyl)-urea 
• 80981-26-6 3-Ethyl-1-methyl-1-(1H-pyrazole-4-carbonyl)-urea 
• 3469-69-0 4-iodopyrazole 
• 67-56-1 methanol 
• 201230-82-2 carbon monoxide 
• 37718-11-9 1H-pyrazole-4-carboxylic acid 
• 875554-08-8 methyl 1-trityl-1H-pyrazole-4-carboxylate 
• 186581-53-3 diazomethane 
• 922-67-8 propynoic acid methyl ester 
• 29097-00-5 3-amino-1H-pyrazole-4-carboxylic acid methyl ester 
• 80981-24-4 1-Ethyl-3-methyl-1-(1H-pyrazole-4-carbonyl)-urea 
• 124-41-4 sodium methylate 
• 80981-23-3 4-ureidocarbonylpyrazole 

Downstream Products

• 571146-13-9 1-[4-(4-dimethoxymethyl-piperidine-1-sulfonyl)-phenyl]-1H-pyrazole-4-carboxylic acid methyl ester 
• 860807-42-7 1-(hydroxymethyl)-4-methoxycarbonyl-1H-pyrazole 
• 1318759-81-7 methyl 6-(dibenzylamino)-5-methylnicotinate 
• 4634-13-3 methyl 6-phenylnicotinate 
• 5571-03-9 methyl 2-methylpyrimidine-5-carboxylate 
• 64074-29-9 methyl 2-phenylpyrimidine-5-carboxylate 
• 861135-98-0 methyl 1-cyclohexyl-1H-pyrazole-4-carboxylate 
• 176240-74-7 methyl 2-isopropylpyrimidine-5-carboxylate 
• 871251-66-0 methyl 2-[4-(trifluoromethyl)phenyl]pyrimidine-5-carboxylate 
• 861135-90-2 methyl 1-benzylpyrazole-4-carboxylate 
• 87551-45-9 1H-pyrazole-4-carbohydrazide 

Relevant articles and documents

HALOALLYLAMINE COMPOUNDS AND APPLICATION THEREOF

The present invention relates to the technical field of pharmaceuticals. Specifically, the present invention relates to a halo-allylamine compound, or a pharmaceutically acceptable salt, an ester, a stereoisomer or a tautomer thereof, and a pharmaceutical formulation and a pharmaceutical composition comprising the compounds, and use in preventing and/or treating a disease related to or mediated by the SSAO/VAP-1 protein,wherein R1, R2, R3, R4, R5, R6, L1 and Cy1 are defined in the specification.

FUMAGILLOL COMPOUNDS AND METHODS OF MAKING AND USING SAME

Disclosed herein, in part, are fumagillol compounds and methods of use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making fumagillol compounds are provided. The compounds are contemplated to have activity against methionyl aminopeptidase 2.

Silica supported palladium-phosphine as a reusable catalyst for alkoxycarbonylation and aminocarbonylation of aryl and heteroaryl iodides

Silica-supported palladium phosphine complexes were prepared for alkoxycarbonylation and aminocarbonylation of aryl iodides. These catalysts were highly efficient for the carbonylation of unprotected hydroxy-aryl, amino-aryl, iodoindole and iodopyrazole. The carbonylation of unprotected iodopyrazole is challenging and their carbonylation was achieved for the first and obtained corresponding carbonylative products are biologically active. The applicability of developed protocols tolerates wide range of functional groups with excellent yields. The catalyst was easily recovered and shows significant recyclability up to five consecutive cycles without loss in its catalytic activity and selectivity. The prepared catalysts were characterized by different techniques such as FEG-SEM, EDS, FT-IR, XPS and ICP-AES spectroscopy.